We identified that Anthraquinones, flavonoids and triterpenoids are considered potential active components in RP by network pharmacology, and the results of KEGG enrichment highlight the potential of RP as the target to treat EMs by inducing apoptosis, P53 signalings. The gene discussed is TP53; the disease is eosinophilia-myalgia syndrome.